Recombinant Human EDIL3 (C-6His)
- Cat. No.：EPT076
- Price：USD $ 2,640.00
- Clicks：1489
Product Detail
Basic Information
| Size | 50ug |
|---|
| Expression Host | Human Cells |
|---|
| Tag | C-6His |
|---|
Physical Properties
| Molecular Weight | 53.09 KDa |
|---|
| Apparent Molecular Weight | 55-65 KDa, reducing conditions |
|---|
| Form | Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 300mM NaCl, pH8.0. |
|---|
| Purity | Greater than 95% as determined by reducing SDS-PAGE. |
|---|
Activity & Endotoxin
| Endotoxin Level | Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test. |
|---|
Storage & Shipping
| Storage | Store at ≤-70°C, stable for 6 months after receipt.
Store at ≤-70°C, stable for 3 months under sterile conditions after opening.
Please minimize freeze-thaw cycles. |
|---|
| Shipping Condition | The product is shipped on dry ice/polar packs.
Upon receipt, store it immediately at the temperature listed below. |
|---|
Detailed Description
| Background | EGF-Like Repeat and Discoidin I-Like Domain-Containing Protein 3 (EDIL3) is a 52 kDa extracellular matrix protein that is expressed by endothelial tissues during embryonic vascular development. EDIL3 becomes quiescent at the time of birth, and is no longer expressed in normal adult tissues. EDIL3 has been found to be re-expressed in a number of human tumors as well as in ischemic muscles and ischemic brain tissue, which may play an important role in adult angiogenesis. EDIL3 promotes adherence and migration of endothelial cells, and acts as an endothelial cell survival agent through upregulation of Bcl-2 expression. EDIL3 has also been shown to be an endogenous inhibitor of inflammatory cell recruitment by interfering with the integrin LFA-1-dependent leukocyte-endothelial adhesion. Human EDIL3 is synthesized as a precursor with a 16 amino acid signal sequence and a 464 amino acid mature chain. |
|---|
